ClinicalTrials.gg
CompletedNCT02652130Updated Mar 16, 2022Results posted

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

A Phase 3 interventional study of Remestemcel-L in Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease and Grade D Acute Graft Versus Host Disease, sponsored by Mesoblast, Inc.. Completed at 20 sites in United States. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
2 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
181st of 389
32 · median 30
Started
2015
with 17 others
Phase 3
40 of 454
2 open now
Registered
306th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 181st largest by enrollment of the 389 interventional ones that give a count, is one of 18 that started in 2015, is one of 40 in phase 3, and was the 306th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 2 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticosteroid therapy.

Read the detailed description

This is a safety follow-up study through 180 days of remestemcel-L treatment in participants who took part in MSB-GVHD001. This study will also explore duration of response over time. Participants who took part in in MSB-GVHD001 and received at least one dose of remestemcel-L as outlined in that protocol will be evaluated at baseline (Day 100) and at Days 120, 140, 160 and 180 for safety endpoints. Participants who took part in Protocol MSB-GVHD001 and received the first 8 doses of remestemcel-L as outlined in that protocol will be evaluated at baseline (Day 100) and at Days 120, 140, 160 and 180 after initial remestemcel-L infusion for evidence of duration of response over time.

03

Conditions studied

  • Grade B Acute Graft Versus Host Disease
  • Grade C Acute Graft Versus Host Disease
  • Grade D Acute Graft Versus Host Disease

Browse trials for

Keywords

  • GVHD
04

Who can participate

Ages eligible
2 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have participated in MSB-GVHD001 and have received at least one infusion of remestemcel-L.
  • Participant or participant's authorized representative must be capable of providing written . Assent, if applicable, must also be collected when required by the Institutional Review Board (IRB)/Ethics Committee (EC).
  • Female participants of (≥ 10 years of age) must use a medically accepted method of and must agree to continue use of this method for the duration of the study and for the follow-up time period. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
  • The participant must be willing and able to comply with study procedures, remain at the clinic as required during the study period, and return to the clinic for the follow-up evaluation as specified in this protocol.

Exclusion criteria

Exclusion Criteria:

  • The investigator believes it to be in the best interest of the participant not to participate in the safety follow-up study.
  • Participant has participated or is currently participating in any autologous or allogeneic stem cell or gene therapy study for the treatment of aGVHD. Participants participating in investigative protocols aimed at modification of the transplant graft (such as T cell depletion) or aimed at modification of the conditioning regimen will be allowed in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Safety population

    All participants who were enrolled and had received at least 1 dose of remestemcel-L in Study MSB-GVHD001.

    Biological: Remestemcel-L

Interventions

  • BiologicalRemestemcel-L

    No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.

06

What researchers measure

Primary outcomes

  1. Overall Survival Rate Through Day 180

    The overall survival rate is defined as the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy.

    Time frame: From Baseline Day 1 in the Study MSB-GVHD001 up to Day 180 in Study MSB-GVHD002 (180 days)

Secondary outcomes

  1. Overall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD001

    The overall survival rate is defined as the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy.

    Time frame: From Baseline (Day 1) in the Study MSB-GVHD001 up to Day 180 in the Study MSB-GVHD002 (180 days)

07

Results

Posted Mar 16, 2022

Participant flow

54 participants enrolled in Study MSB-GVHD001 \[NCT02336230\], received \>=1 dose of remestemcel-L; evaluated up to Day100. These participants were followed-up for OS, GVHD activity up to Day180 (end of Study MSB-GVHD002 \[NCT02652130\]). 32 of 54 participants were enrolled in Study MSB-GVHD002; evaluated at Baseline (Day 100) and at Days120, 140, 160 and 180.

Participant flow — Overall Study
MilestoneRemestemcel-L
Started32
Completed31
Not completed1
Withdrew: Death1

Outcome measures

PrimaryOverall Survival Rate Through Day 180

The overall survival rate is defined as the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy.

Time frame:
From Baseline Day 1 in the Study MSB-GVHD001 up to Day 180 in Study MSB-GVHD002 (180 days)
Reported as:
Number · percentage of participants
Overall Survival Rate Through Day 180
percentage of participantsRemestemcel-L
Overall Survival Rate Through Day 18068.5
SecondaryOverall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD001

The overall survival rate is defined as the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy.

Time frame:
From Baseline (Day 1) in the Study MSB-GVHD001 up to Day 180 in the Study MSB-GVHD002 (180 days)
Reported as:
Number · percentage of participants
Overall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD001
percentage of participantsRemestemcel-L
Overall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD00178.9

Adverse events

Collected over Baseline (Day 100) up to Day 180 in Study MSB-GVHD002. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remestemcel-L1/32 (3.1%)15/32 (46.9%)0/32 (0%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventRemestemcel-L
PneumoniaInfections and infestations2/32
Septic shockInfections and infestations2/32
Febrile neutropeniaBlood and lymphatic system disorders1/32
ThrombocytopeniaBlood and lymphatic system disorders1/32
Pneumatosis intestinalisGastrointestinal disorders1/32
HaematocheziaGastrointestinal disorders1/32
Oedema peripheralGeneral disorders1/32
CholecystitisHepatobiliary disorders1/32
BacteraemiaInfections and infestations1/32
Bronchopulmonary aspergillosisInfections and infestations1/32

Baseline characteristics

Safety population included all participants who signed the informed consent form and received at least one dose of study treatment (complete or partial) in the study MSB-GVHD001 and who signed the informed consent form for the study MSB-GVHD002 were followed across both the studies MSB-GVHD001 and MSB-GVHD002.

Age, Continuous
Age, Continuous(years)Remestemcel-L
Mean7.8 ± 5.24
Sex: Female, Male
Sex: Female, Male(Participants)Remestemcel-L
Female11
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Remestemcel-L
Hispanic or Latino12
Not Hispanic or Latino20
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Remestemcel-L
Race — White20
Race — Black or African American3
Race — Asian2
Race — American Indian or Alaska Native1
Race — Other6
08

Study locations

20 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • CHOC Children's Hospital of Orange County
    Orange, California 92868, United States
  • UCSF Benioff Children's Hospital
    San Francisco, California 94143, United States
  • Children's Hospital Colorado Center for Cancer/Blood Disorders
    Aurora, Colorado 80045, United States
  • Alfred I. duPont Hospital for Children of the Nemours Foundation
    Wilmington, Delaware 19803, United States
  • Miami Children's Research Institute
    Miami, Florida 33155, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10174, United States
  • The Children's Hospital at Montefiore
    New York, New York 10467, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23284, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jun 2018, 31 months.

Results were first posted in Mar 2022, 3 years 9 months after primary completion.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2015
First posted
Jan 11, 2016
StartActual
Oct 28, 2015
Primary completionActual
Jun 15, 2018
CompletionActual
Jun 15, 2018
Results first posted
Mar 16, 2022
Last update
Mar 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02652130
Lead sponsor
Mesoblast, Inc.
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Oct 28, 2015
Primary completion
Jun 15, 2018
Completion
Jun 15, 2018
Results posted
Mar 16, 2022
Last update
Mar 16, 2022

Study contacts

Christopher James
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion